RCKT Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases i…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) said September 15 that the FDA agreed to count three patients treated under the modified RP-A501 protocol toward the pivotal Phase 2 efficacy cohort of 12 male patients. Nine additional patients remain to be enrolled and treated, with dosing expected to finish by mid-2027. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is developing RP-A501 […] | ||
 Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs. | ||
 RCKT Aligns With FDA on Completing Phase II Study in Danon Disease Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion. | ||
 Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls | ||
 Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More As the Federal Reserve prepares to move on rates and oil prices surge past $105, Wednesday's top analyst calls reveal which travel giants, homebuilders, and financial stocks Wall Street is quietly repositioning around before the dust settles. | ||
 Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial. | ||
 Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial Rocket Pharmaceuticals (NASDAQ:RCKT) shares rose 8% on Tuesday after the company said it reached alignment with the US Food and Drug Administration on the pivotal Phase 2 trial of RP-A501 for Danon disease. The FDA confirmed a pivotal efficacy population of 12 patients, including the first three patients treated under the study’s modified protocol, according to Rocket. | ||
 Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose. | ||
 Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report? AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps. | ||
Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says Rocket Pharmaceuticals' (RCKT) Q2 update confirmed its programs are on track, with management expect | ||